Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31563047 | 1.00 | ERN1 (0.36) | ERN1BTKNFE2L2MCL1MEN1 | |
| SCHEMBL746493 | 0.79 | ERN1 (0.44) | ERN1ALDH1A1 | |
| SCHEMBL29954802 | 0.79 | ERN1 (0.37) | ERN1BTKNFE2L2MEN1KMT2A | |
| SCHEMBL441518 | 0.79 | ERN1 (0.37) | ERN1BTKNFE2L2MEN1KMT2A | |
| SCHEMBL23813678 | 0.79 | NFE2L2 (0.32) | NFE2L2 | |
| SCHEMBL772591 | 0.78 | ERN1 (0.46) | ERN1BTKNFE2L2MEN1KMT2A | |
| SCHEMBL16333419 | 0.78 | AURKA (0.40) | ERN1BTKNFE2L2MEN1KMT2A | |
| SCHEMBL438652 | 0.78 | NFE2L2 (0.42) | ERN1BTKNFE2L2MEN1KMT2A | |
| SCHEMBL25230147 | 0.78 | ERN1 (0.36) | ERN1BTKNFE2L2MEN1KMT2A | |
| SCHEMBL29143970 | 0.75 | NFE2L2 (0.37) | ERN1BTKNFE2L2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595273-B2 | Phosphonate conjugates and uses thereof | TRANSLATIONAL GENOMICS RES INST (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4713319-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-25 | — | — | EP | disclosed |
| EP-4619407-A1 | PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 | Curadev Pharma Ltd (GB) | 2025-09-24 | — | — | EP | disclosed |
| US-20250282794-A1 | PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 | CURADEV PHARMA LTD (GB) | 2025-09-11 | — | — | US | disclosed |
| WO-2025077767-A1 | NOVEL I-TYPE TOPOISOMERASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊维康医药有限责任公司 | 2025-04-17 | — | — | WO | disclosed |
| WO-2025077773-A1 | NOVEL TYPE I TOPOISOMERASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊维康医药有限责任公司 | 2025-04-17 | — | — | WO | disclosed |
| WO-2024236528-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024105364-A1 | HETEROCYCLIC INHIBITORS OF CDC-LIKE KINASES | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024105363-A1 | PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| WO-2023156864-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-24 | — | — | WO | disclosed |
| CN-1323203-A | FC receptor modulators and uses thereof | ILEXUS PTY LTD (AU) | 2001-11-21 | — | — | CN | disclosed |
| EP-1109545-A1 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LTD (AU) | 2001-06-27 | — | — | EP | disclosed |
| US-6063923-A | Preparation of a camptothecin derivative by intramolecular cyclisation | GLAXO WELLCOME INC. (US) | 2000-05-16 | — | — | US | disclosed |
| WO-2000015214-A1 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LIMITED (US) | 2000-03-23 | — | — | WO | disclosed |
| US-5840898-A | Method of removing heavy metal contaminants from organic compounds | GLAXO WELLCOME, INC. (US) | 1998-11-24 | — | — | US | disclosed |
| EP-0758333-A1 | INTERMEDIATES IN PHARMACEUTICAL CAMPTOTHECIN PREPARATION | GLAXO WELLCOME INC. (US) | 1997-02-19 | — | — | EP | disclosed |
| EP-0758335-A1 | PREPARATION OF A CAMPTOTHECIN DERIVATIVE BY INTRAMOLECULAR CYCLISATION | GLAXO WELLCOME INC. (US) | 1997-02-19 | — | — | EP | disclosed |
| US-5491237-A | Intermediates in pharmaceutical camptothecin preparation | GLAXO WELLCOME INC. (US) | 1996-02-13 | — | — | US | disclosed |
| WO-1995029917-A2 | INTERMEDIATES IN PHARMACEUTICAL CAMPTOTHECIN PREPARATION | GLAXO WELLCOME INC. (US) | 1995-11-09 | — | — | WO | disclosed |
| WO-1995029919-A1 | PREPARATION OF A CAMPTOTHECIN DERIVATIVE BY INTRAMOLECULAR CYCLISATION | GLAXO WELLCOME INC. (US) | 1995-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282794-A1 | PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 | PDXK, PGK1, CMPK1 | ERN1 559/4885BTK 1281/4885NFE2L2 1949/4885 |
| US-12595273-B2 | Phosphonate conjugates and uses thereof | RET, PTK2, ERBB2 | ERN1 2560/4885BTK 38/4885NFE2L2 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.